Develops DARPin therapies for ophthalmology and oncology, focusing on novel biologics and multi-specific proteins.
Molecular Partners AG is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic proteins. At the forefront of their pipeline is Abicipar, a DARPin therapeutic candidate currently undergoing Phase III clinical trials for neovascular wet age-related macular degeneration and diabetic macular edema. The company also develops MP0420, a multi-specific DARPin therapeutic candidate targeting the SARS-CoV-2 virus.
Additionally, Molecular Partners is advancing MP0310, in Phase Ia trials for immuno-oncology, and MP0317, a tumor-localized immune agonist designed to activate immune cells within tumors, currently in Phase I trials. Their portfolio includes MP0274 for HER2-positive cancers, MP0423 for COVID-19, MP0533 as a CD3 T cell candidate for acute myeloid leukemia, and MP0250 aimed at increasing the half-life of vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin.
Founded in 2004 and headquartered in Schlieren, Switzerland, Molecular Partners AG collaborates extensively with industry leaders such as Novartis AG, Amgen SA, and Allergan, Inc. They also maintain a discovery alliance with AbbVie Inc. focused on ophthalmology. Through strategic partnerships and a robust pipeline, Molecular Partners AG continues to innovate in biopharmaceuticals, aiming to deliver novel therapies that address significant medical needs globally.